Protocolo terapéutico de los antiagregantes y anticoagulantes en la cardiopatía isquémica

  1. Abellas Sequeiros, M. 1
  2. García Sebastián, C. 1
  3. Monteagudo Ruiz, J.M. 1
  4. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Título do exemplar: Enfermedades cardiovasculares (IV)

Serie: 13

Número: 38

Páxinas: 2207-2210

Tipo: Artigo

DOI: 10.1016/J.MED.2021.07.007 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Patients with ischaemic heart disease, with or without revascularisation, are at high thrombotic risk. Therefore, management is based on different combinations of anti-thrombotic therapy. However, these patients are often older or have comorbidities that increase their bleeding risk when taking these medications. Therefore, it is important to assess both ischaemic and bleeding risk, using risk scales, and to select the most appropriate treatment regimen tailored to each patient.

Referencias bibliográficas

  • Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367.
  • Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851-64.
  • Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-6
  • Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31): 2632-53.
  • Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual patient datasets from clinical trials. Lancet. 2017;389(10073):1025-34.
  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck Brentano C. 2019 ESC Guidelines for the diagnosis and ma-nagement of chronic coronary syndromes. Eur Heart J. 2020;41(3): 407-77.
  • Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta analysis of individual participant data from randomised trials. Lancet. 2009;373(9678): 1849-6
Fonte de datos: Dialnet